Beta-interferons in multiple sclerosis: A single center experience in India

Annals of Indian Academy of Neurology

Volumn 13, Issue 2, 2010, Pages 132-135

  Gupta, Salil ^a   Varadarajulu, R ^a   Ganjoo, R K ^a  

^a Medical Division   (India)

Author keywords

Adverse events; beta interferon; Indian patients; multiple sclerosis

Indexed keywords

BETA1A INTERFERON; INTERFERON BETA SERINE; PARACETAMOL; STEROID;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DEPRESSION; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; HUMAN; INDIA; INJECTION SITE PAIN; LEUKOPENIA; MALE; MULTIPLE SCLEROSIS; MYALGIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; RELAPSE; SUICIDAL IDEATION; TREATMENT OUTCOME;

EID: 77954225813     PISSN: 09722327     EISSN: 19983549     Source Type: Journal    
DOI: 10.4103/0972-2327.64624     Document Type: Article

References (21)

1. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing remitting multiple sclerosis: Clinical results of a multicenter randomized, double blind, placebo controlled trial. Neurology 1993;43:655-661
2. Weinstock-Guttman B, Ransohoff RM, Kinkel RP, Rudick RA. The interferons: Biological effects, mechanisms of action and use in multiple sclerosis. Ann Neurol 1995;37:7-15.
3. Arnason BG. Interferon beta in multiple sclerosis. Clin Immunol Immunopath 1996;81:1-11.
4. Singhal BS, Wadia NH. Profi le of patients of multiple sclerosis in Bombay region. J Neurol Sci 1975;26:259-270
5. Bharucha NE, Bharucha EP, Wadia NH, Singhal BS, Bharucha AE, Bhise AV, et al. Prevalence of multiple sclerosis in the Parsis of Bombay. Neurology 1988;38:722-729
6. Kuroiwa Y, Shibashaki H, Tabira T. Clinical picture of multiple sclerosis in Asia. In: Multiple sclerosis - East and West. Kuroiwa Y, Kurland LT, editors. Japan: Kyushu University Press Fukuoka; 1982. p. 43-47
7. Chopra JS, Radhakrishnan K, Sawhney B, Pal SR, Banerjee AK. Multiple sclerosis in North West India. Acta Neurol Scand 1980;62:312-321
8. Gangopadhyay G, Das SK, Sarda P, Saha SP, Gangopadhyay PK, Roy TN, et al. Clinical profi le of multiple sclerosis in Bengal. Neurol India 1999;47:18-21.
9. Syal P, Prabhakar S, Thussu A, Sehgal S, Khandelwal N. Clinical profi le of multiple sclerosis in north-west India. Neurol India 1999;47:12-17
10. Bhatia M, Behari M, Ahuja GK. Multiple sclerosis in India: AIIMS experience. J Assoc Physicians India 1996;44:765-767
11. Singhal BS. Multiple sclerosis: Indian experience. Ann Acad Med Singapore 1985;14:32-36
12. Bansil S, Singhal BS, Ahuja GK, Ladiwala U, Behari M, Friede R, et al. Comparison between multiple sclerosis in India and the United States: A case-control study. Neurology 1996;46:385-387
13. McDonald WI, Compston A, Ednan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2001;50:121-127
14. Barkhof F, Filippi M, Miller DH, Scheltens P, Campi A, Polman CH, et al. Comparison of MRI criteria at first presentation to predict conversion to clinically defi nite multiple sclerosis. Brain 1997;120:2059-2069
15. Tintore M, Rovira A, Martinez MJ, Rio J, Díaz-Villoslada P, Brieva L, et al. Isolated demyelinating syndromes: Comparison of different MR imaging criteria to predict conversion to clinically defi nite multiple sclerosis. AJNR Am J Neuroradiol 2000;21:702-706
16. Lublin FD, Reingold SC. Defi ning the clinical course of multiple sclerosis: Results of an international survey: National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996;46:907-911
17. Kurtzke JF. Rating neurological impairment in MS: An Expanded Disability Status Scale (EDSS). Neurology 1983;33:1444-1452
18. Walther EU, Hohlfeld R. MS: Side effects of interferon beta therapy. Neurology 1999;53:1623-1627
19. Lublin FD, Whitaker JN, Eidelman BH, Miller AE, Arnason BG, Burks JS. Management of patients receiving interferon beta 1b for multiple sclerosis: Report of consensus conference. Neurology 1996;46:12-18
20. Rudick RA, Cookfair DL, Simonian NA, Ransohoff RM, Richert JR, Jacobs LD, et al. Cerebrospinal fluid abnormalities in a phase III trial of Avonex (IFNbeta-1a) for relapsing multiple sclerosis: The Multiple Sclerosis Collaborative Research Group. J Neuroimmunol 1999;93:8-14.
21. Mani J, Chaudhary N, Ravat S, Shah PU. Multiple sclerosis: Experience in neuroimaging era from western India. Neurol India 1999;47:8-11.